Status:
COMPLETED
Mechanism of Decompensation Evaluation - Aortic Stenosis
Lead Sponsor:
University of Edinburgh
Conditions:
Aortic Stenosis
Myocardial Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Aortic stenosis is the most common heart valve disease requiring intervention in high income countries. It is characterised by progressive valvular thickening, and restriction as well is hypertrophy a...
Eligibility Criteria
Inclusion
- Inclusion Criteria (aortic stenosis group):
- Age over 18
- Severe aortic stenosis with planned aortic valve replacement
- Inclusion Criteria (control group):
- Age over 18
- Planned non-aortic valve cardiac or elective ascending aorta surgery
- Exclusion Criteria (aortic stenosis group):
- Coexistent severe aortic or mitral regurgitation
- Coexistent mitral stenosis greater than mild in severity
- Acute valvular heart disease (e.g. acute mitral regurgitation or endocarditis)
- Acute pulmonary oedema or cardiogenic shock
- Coexistent hypertrophic cardiomyopathy
- Unable to give informed consent
- Exclusion Criteria (control group):
- Significant aortic valve disease (mild aortic stenosis / regurgitation or greater)
- Acute valvular heart disease (e.g. acute mitral regurgitation or endocarditis)
- Acute pulmonary oedema or cardiogenic shock
- Coexistent hypertrophic cardiomyopathy
- Unable to give informed consent
Exclusion
Key Trial Info
Start Date :
September 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03332745
Start Date
September 3 2018
End Date
July 31 2023
Last Update
May 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Edinburgh / NHS Lothian
Edinburgh, Midlothian, United Kingdom, EH164SB